Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 3—March 2011


Laboratory-based Surveillance of Extensively Drug-Resistant Tuberculosis, China

Yunfeng Deng, Yan Wang, Junling Wang, Hui Jing, Chunbao Yu, Haiying Wang, Zhimin Liu, Edward A. Graviss, and Xin MaComments to Author 
Author affiliations: Author affiliations: Shandong Provincial Chest Hospital, Jinan, People’s Republic of China (Y. Deng, Y. Wang, J. Wang, H. Jing, C. Yu, H. Wang, Z. Liu, X. Ma); The Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss, X. Ma)

Main Article

Table 2

Second-line drug resistance of 107 MDR Mycobacterium tuberculosis isolates, People’s Republic of China, November 2004–April 2007*

Drugs No. isolates Rate, %
Overall second-line drug resistance 65 60.7
FQ 57 53.3
AMK 19 17.8
CPM 24 22.4
XDR, total 20 18.7
FQ + AMK 4 3.7
FQ + CPM 4 3.7
FQ + AMK + CPM 5 4.7
FQ + AMK + PAS 2 1.9
FQ + CPM + PAS 3 2.8
FQ + AMK + CPM + PAS 2 1.9

*MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin and levofloxacin); AMK, amikacin; CPM, capreomycin; PAS, para-aminosalicylic acid; XDR, extensively drug-resistant.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO